Ratings by Goldman Sachs (Richard Law)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/26/2026 | Hemab Therapeutics Holdings | COAG | New Coverage | Buy (N/A) |
26.30 (30.71) |
16.77% | Details | |
| 5/12/2026 | Bicara Therapeutics Inc | BCAX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/7/2026 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (N/A) |
|
Details | ||
| 4/6/2026 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2026 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2026 | Bicara Therapeutics Inc | BCAX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/18/2026 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2026 | Rocket Pharmaceuticals | RCKT | Maintain | Sell (N/A) |
|
Details | ||
| 3/2/2026 | Celldex Therapeutics | CLDX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/27/2026 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/11/2026 | Bicara Therapeutics Inc | BCAX | Downgrade | Neutral (Buy) |
14.97 (25.75) |
72.01% | Details | |
| 1/15/2026 | Moonlake Immunotherapeutics | MLTX | Downgrade | Sell (Neutral) |
17.10 (19.59) |
14.56% | Details | |
| 1/13/2026 | Arcus Biosciences | RCUS | New Coverage | Buy (N/A) |
21.01 (29.00) |
38.03% | Details | |
| 1/12/2026 | Crinetics | CRNX | Upgrade | Buy (Neutral) |
53.25 (37.06) |
-30.4% | Details | |
| 12/18/2025 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 12/11/2025 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 11/18/2025 | Nuvalent | NUVL | Maintain | Buy (N/A) |
|
Details | ||
| 10/1/2025 | Moonlake Immunotherapeutics | MLTX | Downgrade | Neutral (Buy) |
6.24 (17.10) |
174.04% | Details | |
| 9/29/2025 | Crinetics | CRNX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/20/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Sell (N/A) |
|
Details | ||
| 7/25/2025 | Arcutis Biotherapeutics Inc. | ARQT | New Coverage | Neutral (N/A) |
14.91 (27.45) |
84.1% | Details | |
| 7/10/2025 | Crinetics | CRNX | New Coverage | Neutral (N/A) |
32.33 (53.25) |
64.71% | Details | |
| 7/1/2025 | Nuvalent | NUVL | New Coverage | Buy (N/A) |
79.68 (123.51) |
55.01% | Details | |
| 5/28/2025 | Rocket Pharmaceuticals | RCKT | Downgrade | Sell (Buy) |
2.33 (3.49) |
49.79% | Details | |
| 4/8/2025 | Viking Therapeutic | VKTX | New Coverage | Neutral (N/A) |
22.62 (36.83) |
62.82% | Details | |
| 3/10/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2025 | Silence Therapeutics | SLN | Maintain | Sell (N/A) |
|
Details | ||
| 3/3/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Neutral (N/A) |
|
Details | ||
| 3/3/2025 | Celldex Therapeutics | CLDX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2025 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2025 | Celldex Therapeutics | CLDX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/26/2025 | Moonlake Immunotherapeutics | MLTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/13/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (N/A) |
|
Details | ||
| 2/11/2025 | Silence Therapeutics | SLN | New Coverage | Sell (N/A) |
5.01 (8.63) |
72.26% | Details | |
| 1/17/2025 | Moonlake Immunotherapeutics | MLTX | Upgrade | Buy (Neutral) |
43.97 (6.24) |
-85.81% | Details | |
| 11/21/2024 | Merus N.V. | MRUS | New Coverage | Buy (N/A) |
43.49 (90.00) |
106.94% | Details | |
| 11/13/2024 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2024 | Rocket Pharmaceuticals | RCKT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/28/2024 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 10/24/2024 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 10/15/2024 | Celldex Therapeutics | CLDX | Maintain | Neutral (N/A) |
|
Details | ||
| 9/30/2024 | Celldex Therapeutics | CLDX | New Coverage | Neutral (N/A) |
32.86 (33.32) |
1.4% | Details | |
| 9/12/2024 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 9/10/2024 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2024 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2024 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2024 | Rocket Pharmaceuticals | RCKT | Maintain | Neutral (N/A) |
|
Details | ||
| 6/11/2024 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 6/6/2024 | Viridian Therapeutic | VRDN | New Coverage | Buy (N/A) |
12.34 (17.57) |
42.38% | Details | |
| 4/2/2024 | Moonlake Immunotherapeutics | MLTX | New Coverage | Neutral (N/A) |
50.23 (19.59) |
-61% | Details | |
| 4/2/2024 | Olema Pharmaceuticals | OLMA | New Coverage | Buy (N/A) |
11.32 (11.38) |
0.53% | Details | |
| 4/2/2024 | Mineralys Therapeutics, Inc. | MLYS | New Coverage | Buy (N/A) |
12.91 (26.16) |
102.63% | Details | |
| 4/2/2024 | Rocket Pharmaceuticals | RCKT | New Coverage | Neutral (N/A) |
26.94 (2.33) |
-91.35% | Details |
